Latest Market News
Shares of Novavax Inc. NVAX, +6.01% hiked up 2.9% in morning trading Tuesday, after the Maryland-based biotechnology company and vaccine manufacture Serum Institute of India Pvt. Ltd. said Novavax’s protein-based COVID-19 vaccine, Covovax, has been granted Emergency Use Authorization (EUA) in India by the Drugs Controller General of India. The vaccine will be made and […]
Stock benchmarks trade mixed but were mostly edging higher Tuesday morning, with the S&P 500 on track for a record close—its 70th of 2021—as investors look toward 2022 with optimism, despite record COVID-19 cases, aided by the spread of the omicron variant. The S&P 500 index SPX, +0.16% was trading up less than 0.1% but […]
STORE Capital Corp. STOR, -0.29% disclosed Tuesday that it has terminated Executive Chairman Christopher Volk “without cause.” As a result, Volk will resign as chairman of the board and as a board member or as manager of any company affiliates. Shares of the real estate investment trust focused on single-tenant operational real estate were little […]
Shares of Digital Turbine Inc. APPS, +3.88% shot up 9.7% in premarket trading Tuesday, putting them on track to post a seventh-straight gain, after the media and mobile communications company announced a multi-year partnership with Alphabet Inc.’s GOOGL, -0.42% Google. With the partnership, Digital Turbine will with with Google Cloud partner SADA to implement Google’s […]
Mercury Systems Inc. MRCY, +1.53% said Tuesday that it has adopted a one-year shareholder rights plan, also known as a “poison pill,” as protection from a hostile takeover during a period in which the aerospace and defense technologies company believes its stock is undervalued. The stock, which were indicated up nearly 4% in premarket trading, […]
Shares of Kiniksa Pharmaceuticals Ltd. KNSA, -1.28% tumbled 15.1% in premarket trading Tuesday, after the biopharmaceutical company said a Phase 3 trial of mavrilimumab for treatment of COVID-19-related acute respiratory syndrome (ARDS) failed to meet the primary efficacy endpoint. The company said a total of 582 patients in the Phase 3 trial were randomized to […]